
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6615236/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an InternationalÂCrossover Study With Randomized, Double-Blind Primary Endpoint. Neuromodulation, 2022, 25, 817-828.	0.8	34
2	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	30
3	Increased Stroke Risk in Patients with Parkinson's Disease with <scp><i>LRRK2</i></scp> Mutations. Movement Disorders, 2022, 37, 225-227.	3.9	9
4	Early downregulation of hsa-miR-144-3p in serum from drug-naÃ⁻ve Parkinson's disease patients. Scientific Reports, 2022, 12, 1330.	3.3	14
5	Lack of Association of Group A Streptococcal Infections and Onset of Tics. Neurology, 2022, 98, .	1.1	16
6	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the Neurological Sciences, 2022, 434, 120148.	0.6	13
7	Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinson's Disease, 2022, 12, 935-955.	2.8	3
8	MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice. Diagnostics, 2022, 12, 55.	2.6	3
9	Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	7
10	Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations― Movement Disorders, 2022, 37, 1119-1120.	3.9	0
11	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
12	Impaired motor cortical plasticity associated with cannabis use disorder in young adults. Addiction Biology, 2021, 26, e12912.	2.6	13
13	Mood in Parkinson's disease: From early―to lateâ€stage disease. International Journal of Geriatric Psychiatry, 2021, 36, 627-646.	2.7	7
14	The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset. Neurobiology of Aging, 2021, 97, 144.e1-144.e3.	3.1	3
15	Association of <scp><i>PICALM</i></scp> with Cognitive Impairment in Parkinson's Disease. Movement Disorders, 2021, 36, 118-123.	3.9	7
16	Mutational spectrum of GNAL , THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review. European Journal of Neurology, 2021, 28, 1188-1197.	3.3	2
17	Synaptic processes and immune-related pathways implicated in Tourette syndrome. Translational Psychiatry, 2021, 11, 56.	4.8	31
18	<i>NR4A2</i> Mutations Can Cause Intellectual Disability and Language Impairment With Persistent Dystonia-Parkinsonism. Neurology: Genetics, 2021, 7, e543.	1.9	7

#	Article	IF	CITATIONS
19	3D Printing of Diffuse Low-Grade Gliomas Involving Eloquent Cortical Areas and Subcortical Functional Pathways: Technical Note. World Neurosurgery, 2021, 147, 164-171.e4.	1.3	11
20	A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project. Mechanisms of Ageing and Development, 2021, 194, 111426.	4.6	14
21	Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum. Clinical Nuclear Medicine, 2021, 46, e296-e306.	1.3	2
22	Falls Predict Acute Hospitalization in Parkinson's Disease. Journal of Parkinson's Disease, 2021, , 1-20.	2.8	5
23	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine, 2021, 11, 626.	2.5	10
24	Peripheral Immune Profile and Neutrophilâ€to‣ymphocyte Ratio in Parkinson's Disease. Movement Disorders, 2021, 36, 2426-2430.	3.9	36
25	InÂvivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. Parkinsonism and Related Disorders, 2021, 88, 68-75.	2.2	16
26	Serum lipid profile among sporadic and familial forms of Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 59.	5.3	15
27	Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences, 2021, 11, 1027.	2.3	6
28	Teaching Video Neurolmages: Clues in Myoclonus Evaluation: When to Consider Sialidosis. Neurology, 2021, 97, 10.1212/WNL.000000000012464.	1.1	0
29	Assessment of intellectual impairment, healthâ€related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the <scp>iNTD</scp> registry. Journal of Inherited Metabolic Disease, 2021, 44, 1489-1502.	3.6	7
30	Investigation of gene–environment interactions in relation to tic severity. Journal of Neural Transmission, 2021, 128, 1757-1765.	2.8	2
31	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. Diagnostics, 2021, 11, 1801.	2.6	9
32	Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients. Npj Parkinson's Disease, 2021, 7, 78.	5.3	2
33	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13
34	Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. Tremor and Other Hyperkinetic Movements, 2021, 11, 43.	2.0	8
35	Predictors of clinically significant quality of life impairment in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 118.	5.3	17
36	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics, 2021, 11, 2380.	2.6	2

#	Article	IF	CITATIONS
37	Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges. Neuroscience Letters, 2020, 719, 133679.	2.1	11
38	Orthostatic Myoclonus Secondary to Central Pontine Myelinolysis. Movement Disorders Clinical Practice, 2020, 7, 335-337.	1.5	1
39	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. Neurological Sciences, 2020, 41, 2883-2892.	1.9	13
40	Analysis of p.Tyr307Asn variant in the LRP10 gene in Parkinson's disease in southern Spain. Neurobiology of Aging, 2020, 93, 142.e1-142.e3.	3.1	3
41	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child and Adolescent Psychiatry, 2019, 28, 91-109.	4.7	36
42	Quantitative Intensity Harmonization of Dopamine Transporter SPECT Images Using Gamma Mixture Models. Molecular Imaging and Biology, 2019, 21, 339-347.	2.6	5
43	A replication study of GWAS-genetic risk variants associated with Parkinson's disease in a Spanish population. Neuroscience Letters, 2019, 712, 134425.	2.1	3
44	Raising serum urate levels in Parkinson disease. Neurology, 2019, 93, 611-612.	1.1	1
45	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
46	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.8	111
47	Abnormal cerebellar connectivity and plasticity in isolated cervical dystonia. PLoS ONE, 2019, 14, e0211367.	2.5	25
48	Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. Journal of Parkinson's Disease, 2019, 9, 173-182.	2.8	10
49	Role of ANO3 mutations in dystonia: A large-scale mutational screening study. Parkinsonism and Related Disorders, 2019, 62, 196-200.	2.2	25
50	Increased bilirubin levels in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 213-216.	2.2	18
51	In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. Brain, 2018, 141, 165-176.	7.6	135
52	Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson's disease. Journal of Neurology, 2018, 265, 1279-1287.	3.6	19
53	Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 301-316.	3.2	23
54	TMEM230 in Parkinson's disease in a southern Spanish population. PLoS ONE, 2018, 13, e0197271.	2.5	7

4

#	Article	IF	CITATIONS
55	Automatic and voluntary motor inhibition: Intact processes for tic suppression?. Movement Disorders, 2018, 33, 1667-1669.	3.9	1
56	Clinical, genetic and neuropathological characterization of spinocerebellar ataxia type 37. Brain, 2018, 141, 1981-1997.	7.6	40
57	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
58	Tremor stability index: a new tool for differential diagnosis in tremor syndromes. Brain, 2017, 140, 1977-1986.	7.6	103
59	Genetic analysis of CHCHD2 in a southern Spanish population. Neurobiology of Aging, 2017, 50, 169.e1-169.e2.	3.1	6
60	Abnormal sensorimotor integration correlates with cognitive profile in vascular parkinsonism. Journal of the Neurological Sciences, 2017, 377, 161-166.	0.6	3
61	N370S <i>â€GBA1</i> mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Movement Disorders, 2017, 32, 1409-1422.	3.9	86
62	A Bayesian spatial model for neuroimaging data based on biologically informed basis functions. Neurolmage, 2017, 161, 134-148.	4.2	18
63	Screening study of TUBB4A in isolated dystonia. Parkinsonism and Related Disorders, 2017, 41, 118-120.	2.2	5
64	Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson's Disease, 2017, 2017, 1-8.	1.1	53
65	Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype. PLoS ONE, 2017, 12, e0174644.	2.5	22
66	Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease. PLoS ONE, 2017, 12, e0175560.	2.5	24
67	The long-term outcome of orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309942.	1.9	100
68	GBA Variants Influence Motor and Non-Motor Features of Parkinson's Disease. PLoS ONE, 2016, 11, e0167749.	2.5	91
69	Pre- and perinatal complications in relation to Tourette syndrome and co-occurring obsessive-compulsive disorder and attention-deficit/hyperactivity disorder. Journal of Psychiatric Research, 2016, 82, 126-135.	3.1	36
70	Long-term effectiveness of levodopa–carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease. Neurodegenerative Disease Management, 2016, 6, 289-298.	2.2	25
71	Trait―and stateâ€dependent cortical inhibitory deficits in bipolar disorder. Bipolar Disorders, 2016, 18, 261-271.	1.9	9
72	COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. BMC Neurology, 2016, 16, 26.	1.8	66

#	Article	IF	CITATIONS
73	Low serum uric acid levels in progressive supranuclear palsy. Movement Disorders, 2016, 31, 402-405.	3.9	10
74	The role of mutations in COL6A3 in isolated dystonia. Journal of Neurology, 2016, 263, 730-734.	3.6	15
75	<i>GDNF</i> gene is associated with tourette syndrome in a family study. Movement Disorders, 2015, 30, 1115-1120.	3.9	11
76	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology, 2015, 262, 2201-2213.	3.6	59
77	On the long-term outcome of orthostatic tremor. Parkinsonism and Related Disorders, 2015, 21, 1290-1291.	2.2	2
78	Parieto-motor Cortical Dysfunction in Primary Cervical Dystonia. Brain Stimulation, 2014, 7, 650-657.	1.6	14
79	Clinical features and neuropsychological profile in vascular parkinsonism. Journal of the Neurological Sciences, 2014, 345, 193-197.	0.6	15
80	Analysis of c.801-2A>G mutation in the DNAJC6 gene in Parkinson's disease in southern Spain. Parkinsonism and Related Disorders, 2014, 20, 248-249.	2.2	6
81	Effects of Two Weeks of Cerebellar Theta Burst Stimulation in Cervical Dystonia Patients. Brain Stimulation, 2014, 7, 564-572.	1.6	124